Plus Therapeutics, Inc.
PSTV
$5.50
-$0.03-0.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 60.08% | -46.37% | -53.90% | 275.20% | -433.61% |
| Total Depreciation and Amortization | -39.78% | -58.33% | -61.31% | -54.71% | 16.77% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -91.85% | 7,544.44% | 163.49% | -558.89% | 6,914.61% |
| Change in Net Operating Assets | 70.86% | -157.27% | 907.05% | -272.79% | 10.18% |
| Cash from Operations | -1.07% | -416.68% | 30.76% | -404.17% | -36.76% |
| Capital Expenditure | -27,166.67% | -172.73% | -92.86% | 91.36% | 92.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -318.49% | -1,496.00% | 26,380.00% | -24.29% | 1,189.81% |
| Cash from Investing | -339.83% | -1,782.81% | 14,511.11% | -21.83% | 1,077.47% |
| Total Debt Issued | -73.25% | -- | -- | -100.00% | -- |
| Total Debt Repaid | 84.27% | -- | -- | 100.00% | -1,640.05% |
| Issuance of Common Stock | -- | -- | -- | -58.74% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -10,220.00% | -388.89% | -- |
| Cash from Financing | -27.17% | -- | -- | -59.84% | 1,698.58% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -158.58% | -295.03% | 399.70% | -479.61% | 273.20% |